You just read:

Neurocrine Announces INGREZZA™ (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia has been Accepted for Priority Review by U.S. FDA

News provided by

Neurocrine Biosciences, Inc.

Oct 11, 2016, 06:55 ET